Pfizer commits to offer drugs not-for-profit to 45 low-income countries

Pfizer has announced that it will provide all of its current and future patent-protected medicines and vaccines—that are available in the US or EU—on a not-for-profit basis to 45 lower-income countries.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

The clinical trial dilemma: Navigating European practice

27 November 2025 Clinical trials create a patent paradox. With EPO case law rapidly reshaping the 'expectation of success' test—most recently T136/24—the line between innovation and obviousness is blurred. Amanda Simons of J A Kemp offers drafting strategies to secure protection for your downstream innovations.

Big Pharma

Report reveals surge of AI adoption in IP but lawyers remain cautious

20 November 2025 A new report from Clarivate highlights a jump in the tech’s adoption among IP professionals over the past two years, as well as concerns over governance.

Big Pharma

Sun Pharma and BMS lead 2025 ANDA litigation

10 November 2025 According to new research, generic and brand-name pharma companies are ramping up ANDA litigation with Sun Pharma and Bristol Myers Squibb leading the charge.

More features

PTAB year in review: A shifting landscape and outlook for 2026

UPC: A review of 2025 and what to expect in 2026

Mental health in IP: ‘We have a clear picture of the problem’

From Edwards to Insulet: Three key medical device cases of 2025

Edwards v Meril: Behind the UPC’s landmark medtech showdown

5 ways the USPTO director is changing US innovation

EU unveils sweeping pharma, biotech, and medical device reforms

Mirum targets generics in quartet of suits over liver treatment

Pfizer commits to offer drugs not-for-profit to 45 low-income countries

More on this story

Editor's picks

Editor's picks

More features